How is the skin microbiome measured?
A research-focused overview of methods used to measure the skin microbiome, drawing on registered study protocols that assess microbial communities in conditions such as atopic dermatitis, lymphedema, aging skin, and ros
How is the skin microbiome measured?
The skin microbiome is measured by sampling the skin surface, extracting microbial DNA, and sequencing marker genes or whole communities to identify and quantify microorganisms. In registered research protocols, this measurement is often paired with assessments of skin barrier function, inflammation, and clinical severity. The term “skin microbiome” refers to the community of bacteria, fungi, viruses, and other microorganisms inhabiting the skin; synonyms include skin microbiota and cutaneous microbial flora. No single sequence, formula, or molecular weight defines the skin microbiome as a whole, because it is a complex ecological community rather than a single molecule.
The work centres on characterizing microbial communities and their relationship to skin barrier integrity, immune signalling, and inflammatory pathways, including Th2-related inflammation and antimicrobial peptide expression.
Research Studies
Vernix caseosa retention and atopic dermatitis prevention in newborns
A registered clinical trial is investigating whether retaining vernix caseosa — the white, creamy substance covering newborn skin at birth — can prevent atopic dermatitis (AD) through effects on skin-barrier integrity and the skin microbiome during early life [1]. AD affects up to one in five children worldwide and involves significant itching, discomfort, and sleep disturbance [1]. The study frames primary prevention as a key goal and measures microbiome changes as part of the intervention’s proposed mechanism [1].
Skin microbiome measurement in aging skin and inflammation
The BIA study is a randomized, investigator-blinded, self-controlled pilot trial in older adults with dry skin [3]. Its secondary objectives include determining the extent to which skin microbiome, skin barrier function, and serum inflammation measures change in response to topical moisturizers [3]. The overarching hypothesis is that skin barrier decline contributes to chronic inflammation and that barrier restoration may reduce serum biomarkers of inflammation [3].
Topical ivermectin and the skin microbiome in rosacea
A 16-week open-label study at the University of California, San Diego, is assessing topical ivermectin 1% cream and its effect on protease and antimicrobial peptide expression and on the skin microbiome in rosacea [4]. Investigators measure serine protease activity, cathelicidin, and the skin microbiome at baseline, then instruct participants to apply ivermectin daily for 12 weeks, with monthly visits scoring facial redness and papule counts [4].
Biological profiling of lymphedema: inflammatory and lymphatic markers
An observational, cross-sectional study aims to characterize the biological profile of primary and secondary lymphedema across five domains: Th2-related inflammation, endothelial activation, metabolic dysfunction, lymphatic biology, and tissue fibrosis [2]. While this study does not directly measure the skin microbiome, it illustrates how skin-associated conditions are assessed through multiple biological markers, including inflammatory and lymphatic signalling [2].
Comparing measurement contexts across studies
| Study | Population | Microbiome measurement | Other measures |
|---|---|---|---|
| Vernix caseosa retention [1] | Newborns | Skin microbiome during early life | Skin-barrier integrity, AD incidence |
| BIA study [3] | Older adults with dry skin | Skin microbiome change | Serum inflammation, skin barrier function |
| Ivermectin in rosacea [4] | Adults with rosacea | Skin microbiome | Serine protease activity, cathelicidin, clinical scores |
| Lymphedema profiling [2] | Primary and secondary lymphedema | Not directly measured | Th2 inflammation, endothelial, metabolic, lymphatic, fibrotic markers |
Methodological considerations in skin microbiome research
Across these registered protocols, skin microbiome measurement is integrated with clinical and biomarker assessments to explore relationships between microbial communities and skin health [1][3][4]. The studies vary in design — from randomized pilot trials to observational cross-sectional studies — reflecting the range of approaches used to investigate the skin microbiome in different populations and conditions [1][2][3][4].
If you are reading this for personal health reasons
The materials and information described here are for laboratory research only. We do not provide dosing, medical guidance, or treatment advice. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Retention of Vernix Caseosa in Newborns for Primary Prevention of Atopic Dermatitis
- [2] Biological Profile of Primary and Secondary Lymphedema: Inflammatory, Endothelial, Metabolic, Lymphatic, and Fibrotic Markers
- [3] Skin Barrier Function and Inflammation in Aging: The BIA Study
- [4] Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation